Q-Pharma Consulting
ActiveActs, filings and financial milestones
Deadline for the 2026 accounts:
2026
13-04
micro format · 109 days before the deadline
2025
31-12
Financial
Highest result from 2023 to 2025net €52,910 ▲145%
The operating result of €66,740 and the net result of €52,910 are both a record.
02-07
micro format · 29 days before the deadline
2024
01-08
micro format · 1 day late
2023
07-07
Gazette deed
IncorporationStarting capital €1,000 · Appointment: VAN DINGENEN Jonas (director) · Founder8 points ▸
Gazette deed
Incorporation
Starting capital €1,000 · Appointment: VAN DINGENEN Jonas (director) · Founder8 points ▸
- Incorporation, “Q-Pharma Consulting” (deed in Dutch)
- Founder, VAN DINGENEN Jonas (comparant)
- Founding capital, €1,000
- Bank account, 20-06-2023
- Registered office clause, “2830 Willebroek,Heindonksesteenweg 259” (deed in Dutch)
- Board rule, 1
- Director appointment, VAN DINGENEN Jonas (director (not named in the articles))
- Pre-incorporation commitments, “takeover, alle verbintenissen en verplichtingen en alle activiteiten in naam en voor rekening van vennootschap in oprichting” (deed in Dutch)
Financial milestoneGazette deedNBB filingFinancial milestones sit on the financial year-end date, not the filing date.
Sources:Publications in the Belgian Official GazetteFilings with the National Bank